LncRNA UCA1 in anti-cancer drug resistance

Haohao Wang; Zhonghai Guan; Kuifeng He; Jiong Qian; Jiang Cao; Lisong Teng

doi:10.18632/oncotarget.18344

LncRNA UCA1 in anti-cancer drug resistance

Oncotarget. 2017 Jun 2;8(38):64638-64650. doi: 10.18632/oncotarget.18344. eCollection 2017 Sep 8.

Authors

Haohao Wang^{1

2}, Zhonghai Guan¹, Kuifeng He^{1

2}, Jiong Qian¹, Jiang Cao³, Lisong Teng^{1

2}

Affiliations

¹ Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.
² Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, P.R. China.
³ Clinical Research Center, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.

Abstract

The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.

Keywords: UCA1; cancer; chemoresistance; long non-coding RNA.

Publication types

Review